These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32144987)

  • 1. Cdk5 Inhibitory Peptide Prevents Loss of Neurons and Alleviates Behavioral Changes in p25 Transgenic Mice.
    Huang Y; Huang W; Huang Y; Song P; Zhang M; Zhang HT; Pan S; Hu Y
    J Alzheimers Dis; 2020; 74(4):1231-1242. PubMed ID: 32144987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain.
    Xu M; Huang Y; Song P; Huang Y; Huang W; Zhang HT; Hu Y
    J Alzheimers Dis; 2019; 70(2):573-585. PubMed ID: 31256130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adeno-associated virus 9-mediated Cdk5 inhibitory peptide reverses pathologic changes and behavioral deficits in the Alzheimer's disease mouse model.
    He Y; Pan S; Xu M; He R; Huang W; Song P; Huang J; Zhang HT; Hu Y
    FASEB J; 2017 Aug; 31(8):3383-3392. PubMed ID: 28420695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice.
    Shukla V; Seo J; Binukumar BK; Amin ND; Reddy P; Grant P; Kuntz S; Kesavapany S; Steiner J; Mishra SK; Tsai LH; Pant HC
    J Alzheimers Dis; 2017; 56(1):335-349. PubMed ID: 28085018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson's Disease Mouse Model.
    He R; Huang W; Huang Y; Xu M; Song P; Huang Y; Xie H; Hu Y
    Front Aging Neurosci; 2018; 10():162. PubMed ID: 29910724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the prefrontal cortex after the hippocampus was injected with Aβ
    Wang Y; Sheng H; Zhao J; Guo L; Liu J; Xu J; Liu Q; Huang J; Jiang R; Gan S; Qiu G; Lu W; Xu S; Zhu S
    Neurosci Lett; 2021 Jan; 741():135453. PubMed ID: 33186609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.
    Seo J; Kritskiy O; Watson LA; Barker SJ; Dey D; Raja WK; Lin YT; Ko T; Cho S; Penney J; Silva MC; Sheridan SD; Lucente D; Gusella JF; Dickerson BC; Haggarty SJ; Tsai LH
    J Neurosci; 2017 Oct; 37(41):9917-9924. PubMed ID: 28912154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo.
    Sundaram JR; Poore CP; Sulaimee NH; Pareek T; Asad AB; Rajkumar R; Cheong WF; Wenk MR; Dawe GS; Chuang KH; Pant HC; Kesavapany S
    J Neurosci; 2013 Jan; 33(1):334-43. PubMed ID: 23283346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin Ameliorates Neuroinflammation, Neurodegeneration, and Memory Deficits in p25 Transgenic Mouse Model that Bears Hallmarks of Alzheimer's Disease.
    Sundaram JR; Poore CP; Sulaimee NHB; Pareek T; Cheong WF; Wenk MR; Pant HC; Frautschy SA; Low CM; Kesavapany S
    J Alzheimers Dis; 2017; 60(4):1429-1442. PubMed ID: 29036814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.
    Zheng YL; Amin ND; Hu YF; Rudrabhatla P; Shukla V; Kanungo J; Kesavapany S; Grant P; Albers W; Pant HC
    J Biol Chem; 2010 Oct; 285(44):34202-12. PubMed ID: 20720012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo.
    Nikkel AL; Martino B; Markosyan S; Brederson JD; Medeiros R; Moeller A; Bitner RS
    Neuropharmacology; 2012 Sep; 63(4):606-12. PubMed ID: 22613839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p35 and Rac1 underlie the neuroprotection and cognitive improvement induced by CDK5 silencing.
    Posada-Duque RA; López-Tobón A; Piedrahita D; González-Billault C; Cardona-Gomez GP
    J Neurochem; 2015 Jul; 134(2):354-70. PubMed ID: 25864429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.
    Sun LH; Ban T; Liu CD; Chen QX; Wang X; Yan ML; Hu XL; Su XL; Bao YN; Sun LL; Zhao LJ; Pei SC; Jiang XM; Zong DK; Ai J
    J Neurochem; 2015 Sep; 134(6):1139-51. PubMed ID: 26118667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
    Kesavapany S; Zheng YL; Amin N; Pant HC
    Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.
    Cruz JC; Tseng HC; Goldman JA; Shih H; Tsai LH
    Neuron; 2003 Oct; 40(3):471-83. PubMed ID: 14642273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation.
    Zhao D; Zhou Y; Huo Y; Meng J; Xiao X; Han L; Zhang X; Luo H; Can D; Sun H; Huang TY; Wang X; Zhang J; Liu FR; Xu H; Zhang YW
    Cell Death Differ; 2021 Jan; 28(1):337-348. PubMed ID: 32908202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulforaphene, a CDK5 Inhibitor, attenuates cognitive deficits in a transgenic mouse model of Alzheimer's disease via reducing Aβ Deposition, tau hyperphosphorylation and synaptic dysfunction.
    Yang W; Xu QQ; Yuan Q; Xian YF; Lin ZX
    Int Immunopharmacol; 2023 Jan; 114():109504. PubMed ID: 36508924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration.
    Muyllaert D; Terwel D; Kremer A; Sennvik K; Borghgraef P; Devijver H; Dewachter I; Van Leuven F
    Am J Pathol; 2008 Feb; 172(2):470-85. PubMed ID: 18202185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurodegeneration-Like Pathological and Behavioral Changes in an AAV9-Mediated p25 Overexpression Mouse Model.
    Zhou X; Huang J; Pan S; Xu M; He R; Ji Z; Hu Y
    J Alzheimers Dis; 2016 May; 53(3):843-55. PubMed ID: 27258419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice.
    Bian F; Nath R; Sobocinski G; Booher RN; Lipinski WJ; Callahan MJ; Pack A; Wang KK; Walker LC
    J Comp Neurol; 2002 May; 446(3):257-66. PubMed ID: 11932941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.